hotspot -WSS

hotspot

author：focus 2025-09-30 23:39:15 - browse：37

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Readout Newsletter: New research from Sanofi, Regeneron, etc.

entertainment

WSS

ALS patient reclaims some autonomy thanks to wearable 'robot'

Cheap, fast test for Zika and dengue could cost just $1

CDC recommends rationing of RSV shot due to shortages

Biden's order seeks to regulate AI risk without stifling innovation

Diversifying clinical trials isn't enough to close racial gaps: study

Why Sanofi got shellacked over its spinoff

hotspot

hotspot

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Teladoc has a new CEO, but challenges remain the same

Guidelines to prevent youth baseball injuries need more muscle

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

23andMe had bad news about my health. I wish a person had delivered it

Senate panel to vote on hospitals, PBMs, prisoner care

Medicare details structure of new drug price negotiation program

California wildfire smoke linked to 52,000 early deaths, study says

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

hotspot

Eli Lilly to pay $200M for Beam’s stake in gene

Emergency medicine has repudiated 'excited delirium.' Now what?

ALS patient reclaims some autonomy thanks to wearable 'robot'

The pink breast cancer awareness ribbon needs a redesign

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Diversifying clinical trials isn't enough to close racial gaps: study

focus

entertainment

entertainment

focus